Headline from The Hill
Slide to compare coverage
Center · The Hill
Bias ratings describe an outlet's overall coverage—not whether this particular article is accurate.
FTC: ‘Pharma bro’ Shkreli violated lifetime industry ban, should be held in contempt
The Federal Trade Commission (FTC) and a coalition of seven states asked a federal court on Tuesday to punish Martin Shkreli for “flagrantly and repeatedly” violating a lifetime ban from being involved in the pharmaceutical industry. In a court filing in the U.S. District Court for the Southern District of New York, the FTC said…
Read at The HillChoose a story to feature it above.
The Guardian ·
The Hill ·
BizPac Review ·
left: 1 · center: 3 · right: 1. Counts describe displayed outlets, not independent investigations or the accuracy of their reporting.
Source context: The Federal Trade Commission (FTC) and a coalition of seven states asked a federal court on Tuesday to punish Martin Shkreli for “flagrantly and repeatedly” violating a lifetime ban from being involved in the pharmaceutical industry. In a court filing in the U.S. District Court f…
The wording comparison is calculated from the featured headlines. It is a reading aid; it does not infer an outlet's motives or verify claims. Follow the original sources for evidence and context. See our source directory.
Coverage from 10/13/2026, 1:12:46 PM UTC to 10/13/2026, 8:15:00 PM UTC. A missing source may reflect feed or matching limitations.
Open a headline at its original source, or choose “Show as featured story” to compare it above.
Center Left · The Guardian
Far Right · BizPac Review
Center · The Wall Street Journal
1 publisher
Martin Shkreli’s 2022 release conditions bar him from participating in the pharmaceutical industry, including ownership stakes or business decisionsThe Federal Trade Commission (FTC) and seven US states have alleged that pharmaceutical executive Martin Shkreli repeatedly violated a lifetime ban on participating in the pharmaceutical industry, and they are…
3 publishers
The Federal Trade Commission (FTC) and a coalition of seven states asked a federal court on Tuesday to punish Martin Shkreli for “flagrantly and repeatedly” violating a lifetime ban from being involved in the pharmaceutical industry. In a court filing in the U.S. District Court for the Southern District of New York, the FTC said…
Shkreli was banned from the pharmaceutical industry after a trial found that he organized an illegal scheme to perpetuate a monopoly for the drug Daraprim.
Regulators allege the ex-drug executive held more than 60 pharmaceutical stocks despite a court order barring him from the industry.
1 publisher
A government agency and bipartisan co-plaintiffs from seven states alleged that financier fraudster Martin Shkreli violated his lifetime ban from the pharmaceutical industry. The Federal Trade Commission…
